fda glp-1 warning september 2025 letters compounded FDA Warning Letter Breakdown: Sterility Failures, Subpotent GLP Why the FDA Issued 30
Description
Huang H, Hu C, Liu F, Ji F, Fu Y, Cao M
Clearly the brain/central nervous system effect of these drugs is gaining traction and considerable interest
Weighing Benefits Against Gastrointestinal Risks The documented benefits of GLP-1 therapysustained weight loss, improved metabolic markers, and cardiovascular risk reductionsubstantially outweigh the extremely low incidence of appendicitis reported in clinical populations
But statistical significance doesn't mean every user experiences them equally, individual variation is substantial, and most those who persist past the first 48 weeks report significant improvement
